Fundraising FoxIDrive Ventures — Full Portfolio
4 tracked investments · listed companies and verified rows first
BillionToOne is a precision diagnostics company that uses molecular counting technology to develop non-invasive prenatal screening and liquid biopsy tests for early disease detection.
BiotechDigital HealthHealthtechMedical DevicesSan Francisco, US
Oguzhan Atay(Founder)inDavid Tsao(CTO)inSukrit Silas(Founder)inBrett Huff(Director of Engineering)Mihir Sewak(Software Engineering Manager)Jen Katzburg(Principal Recruiter)
Co-investors500 Emerging Europe500 GlobalAsymmetry VenturesCivilization Ventures Management, Llce2vcFifty Years+23 more
Cymmetria develops deception-based security software that detects and responds to attackers operating inside networks.
CybersecurityEnterprise SoftwareTel Aviv-Yafo, IL
Gadi Evron(CEO)inDean Sysman(CTO)inRan Harel(CPO)
Co-investors408 VenturesFollow[the]SeedLumia CapitalMission and MarketRally Ventures Management, LlcY Combinator+7 more
Unima makes portable diagnostic tests that deliver disease identification at the point of care within 15 minutes at low cost, enabling rapid detection and monitoring of infectious diseases.
BiotechHealthtechMedical DevicesZapopan, MX
Rodrigo Nuno(Interim CTO)inMaria Laura Mendoza(CPO)inAlejandro Nuño Ayala(R\u0026D Director)inLaura Mendoza(Founder)Jose Luis Nuno(CEO)
Co-investorsY CombinatorAgrolimen VenturesAJGAvalancha VenturesInvesto CapitalSP Investment Fund+2 more
Zenflow develops medical devices for treating benign prostatic hyperplasia (BPH) in men, founded from the Stanford Byers Center for Biodesign with a team experienced in medical device development and FDA regulation.
HealthtechMedical DevicesSan Francisco, US
Shreya Mehta(CTO)inNick Damiano(CEO)inJohn Beck(Executive Officer)in
BoardBryan Kim(Director)Robert Weisskoff(Director)inBlayne Roeder(Director)
Co-investorsAstiaCloudStone CapitalDorm RoomF-Prime CapitalShangBay Capital LLCY Combinator+15 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.